What does ISO 10993-10 skin sensitization testing mean in practice?
Skin sensitization according to ISO 10993-10 assesses whether materials, additives, or extractable substances of a medical device can trigger allergic contact dermatitis. This standard forms a central component of the biological evaluation and serves to identify the risk of immunological sensitization at an early stage. Modern testing strategies increasingly rely on animal-free, AOP-based methods that cover several key events of the sensitization pathway.
The most important in vitro/in chemico approaches include kDPRA, KeratinoSens™, and h-CLAT. These methods map different phases of haptenization, keratinocyte activation, and dendritic cell activation, thus providing a robust evidence base. The choice of approach depends on the material type, the duration of exposure, and the likelihood of potentially reactive chemical groups. Combining these methods results in a well-founded overall assessment.
Exposure mapping is performed in accordance with ISO 10993-12. Depending on the product, polar and nonpolar extraction media are used. These parameters ensure that both soluble and sparingly soluble components are captured. A well-documented sampling strategy is crucial to ensure regulatory traceability.
The results of skin sensitization tests are directly incorporated into the biological evaluation according to ISO 10993-1 and influence the risk characterization of the product. Normal results indicate a low allergic risk, while abnormal findings may necessitate a more in-depth toxicological analysis or adjustments to the material composition.
Norm criteria – at a glance
| Norm criterion | Requirement / content | Note |
|---|---|---|
| Risk | Allergic contact dermatitis | Sensitization potential |
| AOP strategy | Cover multiple key events | Stronger evidence |
| Methods (examples) | kDPRA, KeratinoSens™, h-CLAT | Non-animal where applicable |
| Exposure set-up | ISO 10993-12 extracts & surface contact where relevant | Realistic conditions |
| Use of data | Input for ISO 10993-1 | Risk characterization/technical file |
How we test your medical device – step by step
- Request a quote by phone or online. Key inputs: device, materials/components, contact type and exposure duration, and the device condition (e.g., sterilized/reprocessed).
- Send your device after accepting the quote. Please provide the sample in the marketed/used state where possible (including reprocessed state if applicable).
- Upon receipt, we start testing and document sample logistics and - where relevant - ISO 10993-12 aligned preparation/extraction parameters.
- We perform ISO 10993-10 sensitization assessment - preferably using non-animal AOP-based approaches (e.g., kDPRA, KeratinoSens, h-CLAT) aligned with materials, exposure and risk profile.
- You receive a digital, QES-signed report with professional interpretation. Upon request, we coordinate next steps through external toxicology (ISO 10993-17) and the ISO 10993-1 Biological Evaluation.
Why HygCen?
- DAkkS accredited testing laboratory (DIN EN ISO/IEC 17025) with GLP-compliant processes.
- Risk-based study design aligned with intended contact type, duration and use.
- Testing in the original state, including relevant processing/sterilization/reprocessing influences.
- Digital, QES-signed report with expert interpretation for MDR technical documentation.
- One-stop coordination: we manage interfaces to independent toxicologists for ISO 10993-17 and the ISO 10993-1 Biological Evaluation when needed.
An in-vitro/in-chemico strategy is sufficient when device materials exhibit low sensitization risk and chemical characterization reveals no highly reactive structural alerts. kDPRA, KeratinoSens™ and h-CLAT cover multiple AOP key events, enabling a reliable non-animal assessment. However, extraction must follow ISO 10993-12 to simulate realistic exposure conditions, and materials with complex matrices may still require complementary methods.
Typical drivers include reactive monomers, certain adhesives, coatings, additives, dyes and degradation products. Even small quantities of electrophilic functional groups may trigger sensitization. ISO 10993-18 chemical characterization provides essential clues for identifying such risks. When reactive substances are found, test strategies must be strengthened to ensure adequate evidence.
kDPRA evaluates the covalent binding potential of a substance to peptides, representing the first key event of the sensitization AOP. A positive kDPRA result indicates intrinsic reactivity, which may lead to protein binding in vivo. Nevertheless, kDPRA must be interpreted together with KeratinoSens™ and h-CLAT to form a coherent mechanistic understanding that supports risk assessment.
Real use is simulated using risk-based ISO 10993-12 extraction methods and, where necessary, direct surface-contact exposure. These approaches capture both extractable and poorly soluble fractions. For some devices, direct-contact models provide a more realistic exposure scenario, ensuring that sensitization-relevant constituents are not overlooked.
Sensitization results constitute a critical part of the ISO 10993-1 Biological Evaluation. Negative findings support low allergenic concern, whereas positive or inconclusive outcomes require toxicological assessment and may influence the overall risk characterization. This integrated interpretation guides further testing and design decisions.
Related links
ISO 10993-12 – Sample preparation & reference materials, ISO 10993-18 – Chemical characterization, ISO 10993-5 – Cytotoxicity, ISO 10993-23 – Irritation, ISO 10993-3 – Genotoxicity, ISO 10993-4 – Hemocompatibility, Pyrogenicity & endotoxin – incl. ISO 10993-11 coordination, ISO 10993-1 – Biological Evaluation